Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Friday, March 29, 2024 | Back issues
Courthouse News Service Courthouse News Service

Shareholder Class Action

SAN FRANCISCO - Impax Laboratories propped up its stock price with false and misleading statements about its Rytary drug, and the share price dropped from $20 to $14.80 when the truth came out, a shareholder claims in a federal class action.

Categories / Uncategorized

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...